Ribo Presents Kidney-Targeted Delivery Data at ASN Kidney Week 2025

Ribo recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using its RiboPepSTAR™ peptide conjugates. This work highlights the growing validation of Ribo’s Renal platform – designed to silence the right target in the right cell type, specifically in the kidney.

By enabling precise delivery of small interfering RNAs to the kidney, Ribo aims to unlock new possibilities for treating chronic kidney disease (CKD) and improving patient outcomes.

The preclinical data demonstrated proximal tubular specific uptake cross-species from rodents to NHPs with a knock-down efficiency of up to 80%. Also, physiological Proof of Concept has been shown in a rodent model of type 2 diabetes, demonstrating profound kidney specific knock-down of the target gene involved.

Extra-hepatic delivery represents the next frontier in oligonucleotide therapeutics. Ribo will continue to advance its technologies to expand the therapeutic reach beyond the liver, addressing previously inaccessible disease targets.